Loading…
Ultragenyx Pharmaceutical Inc. is projected to rise to $44.36 by 2027, a +31% move from its current price of $33.82. RARE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $32.81 | $33.84 | $34.90 | +0.06% |
| Jul 14 | $32.41 | $33.86 | $35.37 | +0.11% |
| Jul 15 | $32.11 | $33.88 | $35.74 | +0.17% |
| Jul 16 | $31.86 | $33.90 | $36.06 | +0.22% |
| Jul 17 | $31.64 | $33.91 | $36.35 | +0.28% |
| Jul 18 | $31.45 | $33.93 | $36.61 | +0.33% |
| Jul 19 | $31.28 | $33.95 | $36.85 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $31.28 | $33.95 | $36.85 | +0.39% |
| Week 2 | $30.35 | $34.08 | $38.28 | +0.78% |
| Week 3 | $29.69 | $34.22 | $39.44 | +1.18% |
| Week 4 | $29.16 | $34.35 | $40.47 | +1.57% |
| Week 5 | $28.71 | $34.49 | $41.43 | +1.97% |
| Week 6 | $28.32 | $34.62 | $42.32 | +2.37% |
| Week 7 | $27.98 | $34.76 | $43.18 | +2.76% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Ultragenyx Pharmaceutical Inc. (RARE) is a healthcare stock trading at $35.87. It has a market cap of $3.53B and ranks 1645 by market capitalization.
The near-term picture for 2026 shows a neutral stance, with an average price of $35.87, a low of $18.50 and a high of $47.04, and a neutral sentiment.
From 2027 onward, the forecast projects bullish upside, with the 2027 average price of $48.15 rising to $61.18 in 2028 and $85.89 in 2029, and $100.54 in 2030. The horizon continues to show higher levels through 2031–2050, including a 2040 average of $315.16 and a 2050 average of $830.18, with progressively larger max values.
A major floor 52.3% below — a decisive break under it would weaken the trend.
The nearest floor, 36.2% below — buyers have tended to step in here.
The nearest ceiling, 6.1% above — a clean break opens room to run.
A major ceiling 32.2% above — clearing it would confirm fresh momentum.
Key RARE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RARE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $34.53 | Sell | $34.09 | Sell |
| MA 10 | $33.34 | Buy | $33.02 | Buy |
| MA 20 | $30.12 | Buy | $30.81 | Buy |
| MA 50 | $26.50 | Buy | $27.63 | Buy |
| MA 100 | $24.41 | Buy | $26.41 | Buy |
| MA 200 | $27.16 | Buy | $27.57 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 68.05 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 76.70 | Neutral |
| Williams %R (14) | -28.83 | Info |
| MACD (12,26,9) | 0.35 | Buy |
| ROC (12) | 17.59 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 71.17 | Neutral |
| TRIX (15) | 1.30 | Buy |
| Awesome (5,34) | 7.39 | Buy |
| Ultimate (7,14,28) | 61.53 | Neutral |
| Momentum (10) | 4.57 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 35.18 | Sell |
| ADX (14) | 37.18 | Buy |
| ATR (14) | 0.88 | Info |
The 30-day technical picture is bullish, with sentiment listed as BULLISH and RSI14 at 80.
The stock is trading above the key moving averages, with SMA50 at $25.89 and SMA200 at $27.07, indicating a positive short-term trend.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $18.50 | $33.82 | $43.82 | 0% | Neutral | |
| $34.87 | $44.36 | $59.96 | +31% | Bullish | |
| $42.07 | $55.27 | $77.84 | +63% | Bullish | |
| $56.74 | $76.55 | $111.33 | +126% | Bullish | |
| $64.96 | $89.74 | $134.08 | +165% | Bullish | |
| $66.47 | $93.84 | $143.53 | +177% | Bullish | |
| $78.46 | $113.03 | $176.55 | +234% | Bullish | |
| $82.95 | $121.78 | $193.86 | +260% | Bullish | |
| $86.64 | $129.53 | $209.82 | +283% | Bullish | |
| $110.99 | $168.85 | $277.95 | +399% | Bullish | |
| $162.75 | $268.09 | $472.08 | +693% | Bullish | |
| $361.13 | $683.76 | $1,327.44 | +19.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $18.50 | $33.82 | $40.26 | +0.00% |
| August 2026 | $28.84 | $34.16 | $41.63 | +1.00% |
| September 2026 | $29.80 | $35.58 | $43.92 | +4.17% |
| October 2026 | $29.44 | $35.39 | $44.15 | -0.53% |
| November 2026 | $28.25 | $34.17 | $43.00 | -3.46% |
| December 2026 | $28.41 | $34.54 | $43.82 | +1.09% |
Click any year to see its month-by-month RARE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RARE is projected to trade between $18.50 and $43.82, averaging $33.82 — a potential gain of 0% from today's $33.82. A consolidation phase looks the most probable path here.
Ultragenyx Pharmaceutical Inc.'s 2027 outlook centres on $44.36, within a $34.87 to $59.96 range. That is up +31% on the projected 2026 average. That marks a +31% change versus current levels. Momentum favours further upside here.
By 2028, RARE could reach as high as $77.84, with a base case around $55.27 and support toward $42.07 — roughly +63% from $33.82. Buyers look set to stay in control over this stretch.
Expect RARE to range from $56.74 to $111.33 through 2029. The $76.55 average target implies a +126% move from current prices. That is up +39% on the projected 2028 average. Momentum favours further upside here.
The RARE price prediction for 2030 points to an average of $89.74 (low $64.96, high $134.08) — a potential gain of +165% on today's $33.82. Buyers look set to stay in control over this stretch.
In 2031, RARE is projected to trade between $66.47 and $143.53, averaging $93.84 — a potential gain of +177% from today's $33.82. That is up +5% on the projected 2030 average. Momentum favours further upside here.
Ultragenyx Pharmaceutical Inc.'s 2032 outlook centres on $113.03, within a $78.46 to $176.55 range. That is up +20% on the projected 2031 average. That marks a +234% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, RARE could reach as high as $193.86, with a base case around $121.78 and support toward $82.95 — roughly +260% from $33.82. Momentum favours further upside here.
Expect RARE to range from $86.64 to $209.82 through 2034. The $129.53 average target implies a +283% move from current prices. That is up +6% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The RARE price prediction for 2035 points to an average of $168.85 (low $110.99, high $277.95) — a potential gain of +399% on today's $33.82. Momentum favours further upside here.
In 2040, RARE is projected to trade between $162.75 and $472.08, averaging $268.09 — a potential gain of +693% from today's $33.82. That is up +59% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Ultragenyx Pharmaceutical Inc.'s 2050 outlook centres on $683.76, within a $361.13 to $1,327.44 range. That is up +155% on the projected 2040 average. That marks a +19.2x change versus current levels. Momentum favours further upside here.
Investing $1,000 in RARE today (≈ 29.568303 RARE) could be worth
$20,217.75
+$19,217.75 (+1922%) by 2050 · US Dollar
Based on the average projected RARE price of $683.76 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RAREwould be worth at today's price.
$1,000 invested in RARE on Jul 10, 2025 (≈ 32.221685 RARE) would be worth
$1,089.74
+$89.74 (+9.0%) today · 1.09× · US Dollar
Based on a RARE entry price of $31.03 vs. today's $33.82.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $33.47 | $1,010.46 | +1.0% |
| 1 month ago | $22.97 | $1,472.36 | +47.2% |
| 3 months ago | $23.3 | $1,451.5 | +45.2% |
| 6 months ago | $24.37 | $1,387.77 | +38.8% |
| 1 year ago | $31.03 | $1,089.74 | +9.0% |
| All time (5.0y) ago | $87.57 | $386.21 | -61.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RARE forecast.
Our base-case forecast reaches $68.00 around 2029.
Implied market cap at $68.00: $6.7B
The multi-year forecast is bullish across the horizon, with strong upside implied by rising averages and max values. By 2030 the average price is projected at $100.54 with a max of $152.15 and a min of $71.94, yielding an estimated ROI of 180.3 and a bullish sentiment. By 2040 the average price is $315.16 and the max is $565.68, with an ROI of 778.6.
By 2050 the average price is $830.18 and the max is $1,648.28, with an ROI of 2214.4 and continued bullish sentiment.
The forecast also shows substantial upside earlier in the horizon (e.g., 2027 avg $48.15; 2028 $61.18; 2029 $85.89), while the 2026 figure remains neutral at $35.87. These are estimates, not guarantees, and actual results can differ due to market factors and company developments.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg of $100.54, a min of $71.94, a max of $152.15, and a ROI of 180.3 with bullish sentiment.
The 2027–2050 forecast exhibits bullish sentiment with rising averages and ROI, including an avg of $48.15 in 2027 and $830.18 in 2050, though 2026 is neutral at $35.87.
Yes. The forecast for 2035 lists a max of $332.91, with an avg of $198.90 and a min of $128.34.
Current price is $35.87 and market cap is $3.53B.
The 30-day range is $28.91 to $44.51.
Ultragenyx Pharmaceutical Inc. Community Discussion
0Share your Ultragenyx Pharmaceutical Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.